Aqualyx

Description

Aqualyx is a CE-marked (European conformity) injectable fat-dissolving product developed by Marllor (Italy) and widely used in aesthetic and cosmetic clinics for non-surgical body contouring and localized fat reduction. The active ingredient is a modified form of deoxycholic acid (a naturally occurring bile acid), combined with a patented sugar-based delivery system that allows selective targeting of adipocyte (fat cell) membranes. When injected into subcutaneous fat tissue, Aqualyx disrupts adipocyte cell membranes, causing irreversible lysis (cell destruction) and subsequent release of stored triglycerides. The released fat is then gradually cleared by the body’s lymphatic system and metabolized via the liver—leading to a permanent reduction in the number of fat cells in the treated area. Common treatment zones include submental fat (double chin), abdominal fat, love handles, inner/outer thighs, saddlebags, upper arms (bat wings), bra rolls, buffalo hump, and male chest (pseudogynecomastia). Clinical protocols typically involve 2–8 sessions spaced 3–6 weeks apart, with each session using 1–5 vials (8 mL per vial) depending on the area size and fat thickness. Most patients see visible contour improvement after 3–4 treatments, with final results appearing 4–8 weeks after the last session as inflammation resolves and fat clearance completes. Aqualyx is administered via multiple shallow micro-injections using a fine needle or cannula after local anesthesia or numbing cream, often combined with manual massage or ultrasound to distribute the solution and enhance lymphatic drainage. Results are considered long-lasting as destroyed adipocytes do not regenerate, though remaining fat cells can still enlarge with significant weight gain. While generally well-tolerated, common side effects include temporary swelling, bruising, redness, tenderness, itching, or burning at injection sites (lasting 3–14 days), small nodules or lumps (usually resolving spontaneously), and occasional unevenness or asymmetry. Rare but reported complications include prolonged swelling, infection, skin necrosis, nerve injury, or allergic reactions. Aqualyx is not FDA-approved in the United States as of 2026 (where deoxycholic acid is approved only under the brand Kybella for submental fat), but it carries the CE mark and is legally used in many European, Asian, Middle Eastern, and other countries under medical supervision. It is intended for use only by trained aesthetic physicians or dermatologists experienced in injection lipolysis. Proper patient selection is critical—ideal candidates have localized pinchable subcutaneous fat with good skin elasticity, realistic expectations, and no contraindications (active skin infection, uncontrolled diabetes, bleeding disorders, pregnancy/breastfeeding, severe liver/kidney disease, or allergy to deoxycholic acid components). Always combine Aqualyx with healthy diet, regular exercise, and maintenance of stable weight for optimal and lasting results. Consult a qualified aesthetic practitioner for a thorough assessment, realistic outcome discussion, treatment plan, and aftercare instructions. Aqualyx offers a minimally invasive option for body contouring when surgical liposuction is not desired or indicated.